AbCellera IPO Presentation Deck

THE PROBLEM LIMITED TECH & LIMITED ACCESS LIMITS IMPACT Drug developers focus on getting one drug candidate to the finish line. The result is a chronic underinvestment in the technologies to make the process of drug development better. Drug development fails too often, takes too long and costs too much. ~$3 billion The average cost of drug development. + ~9.4 to 12 years AbCellera The time it takes an average antibody drug from initiation to approval. ~90% failure rate

View entire presentation